SIGA TECHNOLOGIES INC (SIGA)
Health Care · Biodefense pharmaceuticals / orthopoxvirus antivirals · NASDAQ
SIGA is a biodefense-focused pharmaceutical company selling tecovirimat (TPOXX®), an FDA-approved smallpox antiviral, primarily to the U.S. Strategic National Stockpile and international governments.
What SIGA TECHNOLOGIES INC does
SIGA Technologies is a commercial-stage pharmaceutical company focused on the development and commercialization of antiviral therapies for serious unmet medical needs, specifically orthopoxviruses. Its lead product is TPOXX (tecovirimat), an antiviral medication approved for the treatment of smallpox, with certain international authorizations covering mpox, cowpox, and vaccinia complications. The company primarily generates revenue through procurement contracts with the U.S. government and various international government entities for the Strategic National Stockpile.
Themes: Smallpox / orthopoxvirus antivirals, Monkeypox (mpox) treatment, Biodefense / Strategic National Stockpile, Rare disease / orphan drug, Government procurement
Fundamentals
- Price$3.04 as of 2026-08-25 close
- Market cap$218M as of 2026-08-25
- 1-year return-65.1% 2025-08-25 close $8.70 → 2026-08-25 close $3.04
- P/E8.94 as of 2026-08-26
- Net margin-5.2% as of 2026-08-26
- Gross margin+54.4% as of 2026-08-26
- ROE-1.6% as of 2026-08-26
- Debt / equity0.00 as of 2026-08-26
- Revenue growth (YoY)-70.1% as of 2026-08-26
- Revenue CAGR (3y)-5.1% SEC XBRL
- Beta0.99 as of 2026-08-26
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +20.9%; at least 4 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How SIGA compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-26
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-26
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-26
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- indicated dividend yieldtop 10% 71 covered Health Care peers, as of 2026-08-26
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, SIGA's dividend exceeded at least one reported measure of what it earned or generated (earnings payout 185%, operating-cash-flow payout 99%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payout185% dividends / net income
- Operating-cash-flow payout99% dividends / operating cash flow — capital spending was not reported, so this does not subtract it
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How SIGA TECHNOLOGIES INC looks technically
SIGA TECHNOLOGIES INC (SIGA) is trading 41.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 164 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive). It made a new 20-day low about 10 trading days ago. It is 67.8% below its highest point of the past year. Trading volume is unusually light — only about 48% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 41.4% below its 200-day average, the long-term trend line — a long-term downtrend | -41.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.46 | $3.46 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.19 | $5.19 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 4.095. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 164 trading days ago — a "death cross", a bearish long-term signal | 164 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control | 32.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30) | 44.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($2.83 to $3.19) — its "stochastic" reading is 58 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 57.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive) | 8 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $9.45 | $9.45 |
|---|---|---|
| From the 52-week high | it is 67.8% below its 52-week high (its highest price of the past year) | -67.8% |
| Above the 52-week low | it is 7.4% above its 52-week low (its lowest price of the past year) | +7.4% |
| Below the 52-week high | it is 67.8% below its highest point of the past year | 67.8% |
| Since a 20-day breakout | it made a new 20-day low about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day low about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $26.99 (set on 2022-08-15) | $26.99 |
| Given back of the 52-week move | over the past year its closes ranged ($2.87 to $9.37), and it has recovered only a small part of its fall from last year’s high — 3% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.89 to $7.09. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 2.6% |
| From the all-time high | it is 88.7% below its all-time high | -88.7% |
| Nearest price level | it is trading 45.2% below a resistance level at $4.42 — a price it turned at twice since 2026-04-21, most recently on 2026-06-22. Since 2024-08-26 it has 0 such levels below the current price and 16 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +45.2% |
| All-time low | its lowest closing price on record is $0.2 (set on 2015-12-24) | $0.2 |
| Above the all-time low | it is 1420.0% above its all-time low | +1,420% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 37th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1502 between its high and its low — about 4.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1502 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.78 and $3.34 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.78 – $3.06 – $3.34 |
| Typical daily range (% of price) | its price moves about 4.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.9% |
| Stretch from the 200-day average | it is trading 14.3 daily ranges below its 200-day average price (41.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 14.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 48% of its 30-day average | 0.48× |
|---|
Analyst
2
| Change in the average price target | not available for this company yet | n/a |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a bearish engulfing | 1 session ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 1 session ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-25 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.7% |
|---|---|---|
| Gap filled | a 3.3% gap up opened on 2026-06-05 has been "filled" 52 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 52 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 5.9 percentage points (the stock lost 2.3% while the market gained 3.7%) | -5.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 37.8 percentage points (the stock lost 35.0% while the market gained 2.7%) | -37.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 65.8 percentage points (the stock lost 55.3% while the market gained 10.5%) | -65.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 84.3 percentage points (the stock lost 65.1% while the market gained 19.2%) | -84.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-20 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 14.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -18.4% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 34% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.62 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -34.1% |
|---|
Price levels it has turned at before
SIGA last closed at $3.04 on 2026-08-25. Since 2024-08-26 it has turned at 0 prices below its last close and 16 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.42 | Resistance | 45.2% above the last close | turned there twice · 2026-04-21 to 2026-06-22 |
| $4.80 | Resistance | 58.0% above the last close | turned there three times · 2026-03-18 to 2026-05-22 |
| $4.93 | Resistance | 62.3% above the last close | turned there twice · 2025-04-04 to 2026-05-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $4.09.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $3.29 and $3.81 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $2.83.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-25.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · lagging the market · Stretched far below its 200-day average (6+ daily ranges) · Trading below the Ichimoku cloud · Elliott wave 4 pullbacks | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-25. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (0.00 mean, 1=Strong Buy…5=Strong Sell)
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Regulatory uncertainty: EMA's Committee for Medicinal Products for Human Use (CHMP) initiated a referral procedure in July 2025 questioning the effectiveness of Tecovirimat-SIGA for mpox treatment, with potential for withdrawal of the mpox indication and potential suspension or withdrawal of the overall marketing authorization.","Revenue concentration and dependency: The company's sales are primarily concentrated to U.S. and international governments through procurement contracts, creating dependency on government demand and budget allocation for Strategic Stockpile acquisitions.","Macroeconomic and supply chain risk: Tariffs and trade policy volatility could materially increase manufacturing costs, particularly for IV TPOXX® which relies on European raw materials, adversely impacting operating results."]
What changed in the latest 10-Q
AI-assisted comparison of SIGA's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 2025 Form 10-K filed March 10, 2026 (newer filing)
- Specification that oral TPOXX® formulation is 'the oral formulation of TPOXX®' (newer filing)
- Details on CHMP's March 27, 2026 opinion confirming positive benefit-risk balance for smallpox, cowpox, and vaccinia complications, recommending removal of mpox indication (newer filing)
- Reference to April 2026 MHRA request to align UK label with referral procedure outcome (newer filing)
- Addition of 'and uncertainty' in macroeconomic discussion regarding tariffs and trade policies (newer filing)
- Addition of 'or other trading restrictions' in IV TPOXX® tariff discussion (newer filing)
- Addition of 'support for manufacturing activities' to BARDA contract funding activities list (newer filing)
- Update of BARDA contract status date from September 30, 2025 to March 31, 2026 (newer filing)
- Removed:
- Phrase 'most recently, in December 2024' regarding PMDA approval (older filing, removed in newer)
- Reference to 2024 Form 10-K filed March 11, 2025 (older filing)
- Reference to Form 10-Q for period ended June 30, 2025 in Risk Factors (older filing)
- Statement that 'EMA will now review' and reference to ongoing MHRA reassessment process (older filing)
- Phrase 'in 2026' for Supplemental NDA submission timing, changed to 'within the next twelve months' (older filing)
- Reworded:
- Supplemental NDA submission timing changed from 'in 2026' (older) to 'within the next twelve months' (newer)
- CHMP referral procedure status changed from prospective review ('EMA will now review') to completed review with issued opinion (newer filing)
- Macroeconomic language expanded from 'changes to tariffs and trade policies' (older) to 'changes to and uncertainty regarding tariffs and trade policies' (newer)
- IV TPOXX® tariff impact language expanded from 'tariff activity' (older) to 'tariff activity or other trading restrictions' (newer)
- BARDA contract funding description now includes 'support for manufacturing activities' as separate item from 'procurement activities' (newer)
- Notes:
- Comparison reflects completion of EMA referral procedure and CHMP opinion between the two filing dates
- Document appears truncated at end of BARDA contract section in both versions, limiting full comparison of that section
- Timing references reflect different quarterly periods (March 31, 2026 vs September 30, 2025)
Risk Factors
- Added:
- Dividend payable of $43,034,458 added to current liabilities as of March 31, 2026 (newer filing)
- Payment of dividend on vested equity awards of $159,380 added to cash flows from financing activities for three months ended March 31, 2026 (newer filing)
- Purchase of manufacturing equipment of $733,862 added to supplemental disclosure of non-cash investing activities for three months ended March 31, 2026 (newer filing)
- Accumulated deficit increased to $(90,442,741) as of March 31, 2026 (newer filing)
- Removed:
- Deferred IV TPOXX® revenue line item removed from current liabilities (older filing showed $10,240,000 as of September 30, 2025; newer filing shows 'Deferred revenue' of $8,884,121 as of March 31, 2026)
- Write down of inventory, net removed from cash flow adjustments (appeared in older filing for nine months ended September 30, 2025)
- Non-cash lease right-of-use asset and associated liability removed from supplemental disclosure (older filing showed $462,686 for nine months ended September 30, 2024)
- Issuance of common stock removed from supplemental disclosure (older filing showed $417,000 for nine months ended September 30, 2024)
- Reworded:
- Reference year changed from 'December 31, 2024' to 'December 31, 2025' in Note 1 (newer filing references 2025 Form 10-K filed March 10, 2026; older filing referenced 2024 Form 10-K filed March 11, 2025)
- Performance obligations description changed from 'four performance obligations relate to research and development services; and one relates to manufacture and delivery of product' (as of September 30, 2025) to 'three performance obligations relate to research and development services; and two relate to manufacture and delivery of product' (as of March 31, 2026)
- Aggregate transaction price allocated to current performance obligations changed from '$59.9 million' (as of September 30, 2025) to '$65.6 million' (as of March 31, 2026)
- Deferred revenue line item renamed from 'Deferred IV TPOXX® revenue' (older filing) to 'Deferred revenue' (newer filing)
- Payment of dividend line item renamed from 'Payment of dividend' (older filing showing $43,028,706 for nine months) to 'Payment of dividend on vested equity awards' (newer filing)
- Notes:
- The two filings cover different reporting periods (three months ended March 31, 2026 vs. nine months ended September 30, 2025), which accounts for significant differences in financial results and metrics
- The balance sheet comparison uses different comparative periods (December 31, 2025 vs. December 31, 2024)
- The cash flow statements cover different periods and are not directly comparable in all respects due to quarterly vs. nine-month presentation
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for SIGA — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SIGA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 5,709,683
- Reported value $30,546,804
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SIGA had 3,692,365 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SIGA had 5.14% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.86 days to cover at the same settlement.
- Reported short interest (shares) 3,692,365
- Short interest (% of shares outstanding) 5.14%
- Prior settlement (shares) 3,932,494
- Reported change -6.11%
- Days to cover (reported) 3.86
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Emergent BioSolutions (EBS)
- Chimerix (CMRX)
- Bavarian Nordic (BVNRY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SIGA vs…
SIGA ranks in…
Frequently asked questions
What does SIGA TECHNOLOGIES INC (SIGA) do?
SIGA Technologies is a commercial-stage pharmaceutical company focused on the development and commercialization of antiviral therapies for serious unmet medical needs, specifically orthopoxviruses. Its lead product is TPOXX (tecovirimat), an antiviral medication approved for the treatment of smallpox, with certain international authorizations covering mpox, cowpox, and vaccinia complications. The company primarily generates revenue through procurement contracts with the U.S.
What sector is SIGA TECHNOLOGIES INC (SIGA) in?
SIGA TECHNOLOGIES INC (SIGA) is classified in the Health Care sector. Its industry is Biodefense pharmaceuticals / orthopoxvirus antivirals. It trades on NASDAQ.
Does SIGA pay a dividend?
Yes — SIGA TECHNOLOGIES INC (SIGA) pays a dividend, with an indicated yield of about 20.94% and at least 4 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-26). Informational only — not financial advice.
Who are SIGA TECHNOLOGIES INC's (SIGA) competitors?
Notable peers of SIGA TECHNOLOGIES INC (SIGA) include Emergent BioSolutions, Chimerix and Bavarian Nordic. This peer set is informational only — not financial advice.
Is SIGA TECHNOLOGIES INC (SIGA) overbought or oversold right now?
SIGA TECHNOLOGIES INC (SIGA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 44, in the neutral middle (as of 2026-08-25). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SIGA come from?
Fundamentals and prices come from market data, as of 2026-08-26; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-25.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.